We decided to use a PI3K inhibitor acting predominantly against PI3K, as it has been largely shown by our team and others that treating BC cells with PI3K inhibitors disrupts ER/PI3K interactions in ER-positive cell lines [13, 15, 21]. The gene discussed is PIK3CA; the disease is breast cancer.